PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Julia:ReplicateBE – release 0.2.0

Опубликовано 26 октября, 201926 октября, 2019 frozencat

doiGitHub

Вот и подоспел релиз 0.2.0 для оценки параметров смешанной модели репликативного дизайна биоэквивалентности по методу С (EMA) – FDA model.

 

Рубрики: IT, Julia, Mixed Model, Биоэквивалентность

Навигация по записям

Предыдущая запись: ClinicalTrialUtilities: обзор
Следующая запись: Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180130 173058
20180814 182629
DJI 0054
20180816 204834
IMG-20170806-WA0001
20180129 175218
  • Human medicines European public assessment report (EPAR): Vocabria, cabotegravir, Date of authorisation: 17/12/2020, Revision: 17, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
  • Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
  • Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, Date of authorisation: 04/03/2013, Revision: 26, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
  • Human medicines European public assessment report (EPAR): Palonosetron Accord, palonosetron, Date of authorisation: 26/05/2016, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
  • Human medicines European public assessment report (EPAR): Enerzair Breezhaler, indacaterol,glycopyrronium bromide,mometasone, Date of authorisation: 03/07/2020, Revision: 10, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
  • Human medicines European public assessment report (EPAR): Zimbus Breezhaler, indacaterol,glycopyrronium,mometasone furoate, Date of authorisation: 03/07/2020, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
  • Biologics Procedures (SOPPs)
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-29 By FDA
  • OTP Events, Meetings, and Workshops
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-29 By FDA
  • Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • Human medicines European public assessment report (EPAR): Fabhalta, iptacopan, Date of authorisation: 17/05/2024, Revision: 5, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • Human medicines European public assessment report (EPAR): Lytgobi, futibatinib, Date of authorisation: 04/07/2023, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • TECARTUS
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-29 By FDA
  • Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 29, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-29
  • Biosimilars Guidances
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-29 By FDA
  • Drugs@FDA Data Files
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-29 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.